MoneyWorks4Me

Windlas Biotech - Quaterly Results

05 May 2023 Evaluate
The Revenue for the quarter ended  March 2023 of Rs. 1407.13 millions grew by 15.21 % from Rs. 1221.31 millions.The Net Profit of the company registered a slight decline of -24.85% to Rs. 114.48  millions from Rs. 152.33 millions.Operating Profit saw a handsome growth to 187.77 millions from 172.90 millions in the quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1407.13 1221.31 15.21 5130.83 4659.30 10.12 5130.83 4659.30 10.12
Other Income 23.34 30.05 -22.33 99.65 67.06 48.60 99.65 67.06 48.60
PBIDT 187.77 172.90 8.60 702.07 596.01 17.80 702.07 596.01 17.80
Interest 1.64 2.88 -43.06 7.86 14.17 -44.53 7.86 14.17 -44.53
PBDT 186.13 170.02 9.48 694.21 581.84 19.31 694.21 581.84 19.31
Depreciation 35.68 29.02 22.95 123.64 121.47 1.79 123.64 121.47 1.79
PBT 150.45 141.00 6.70 570.57 460.37 23.94 570.57 460.37 23.94
TAX 35.97 -11.33 -417.48 144.13 74.76 92.79 144.13 74.76 92.79
Deferred Tax -6.12 -28.50 -78.53 0.63 -26.57 -102.37 0.63 -26.57 -102.37
PAT 114.48 152.33 -24.85 426.44 385.61 10.59 426.44 385.61 10.59
Equity 104.63 108.97 -3.98 104.63 108.97 -3.98 104.63 108.97 -3.98
PBIDTM(%) 13.34 14.16 -5.74 13.68 12.79 6.97 13.68 12.79 6.97
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..